-

Warner Bros. Discovery, Inc. Equity Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Warner Bros. Discovery, Inc. (WBD)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who (1) exchanged Discovery, Inc. common stock for Warner Bros. Discovery, Inc. (NASDAQ: WBD) common stock pursuant or traceable to Discovery’s February 4, 2022 Registration Statement on Form S-4 (the “Registration Statement”) and Joint Proxy Statement/Prospectus filed with the SEC on February 10, 2022 (the “Prospectus”), or (2) purchased shares of WBD common stock on the open market traceable to the Prospectus through the date of the filing of this Complaint. The complaint is also brought on behalf of Discovery shareholders who exchanged Discovery common shares for WBD common stock pursuant to the Prospectus.

If you would like more information about Warner Bros. Discovery, Inc.'s misconduct, click here.

What is this Case About: Defendants Made False and Misleading Statements in Connection with the Merger Between Discovery, Inc. and the WarnerMedia division of AT&T, Inc.

According to the complaint, Discovery and the WarnerMedia division of AT&T, Inc. completed its merger on April 8, 2022. After the merger, Discovery's former senior officers – named as individual defendants in the class action – managed WBD. At the time of filing the Registration Statement and Prospectus, Discovery and the individual defendants knew or had access to adverse information concerning operations of the WarnerMedia business. However, defendants failed to disclose this information to Discovery shareholders prior to the vote on the merger.

Specifically, defendants failed to disclose that: (i) WarnerMedia’s HBO Max streaming business had a high churn rate that made the business not “viable” unless the churn rate was reversed; (ii) AT&T was overinvesting in WarnerMedia entertainment content for streaming, without sufficient concern for return on investments; (iii) WarnerMedia had a business model to grow the number of subscribers to its streaming service without regard to cost or profitability; (iv) WarnerMedia was improvidently concentrating its investments in streaming and ignoring its other business lines; and (v) WarnerMedia had overstated the number of subscribers to HBO Max by as many as 10 million subscribers, by including as subscribers AT&T customers who had received bundled access to HBO Max, but had not signed onto the service.

Between April 11, 2022, the first trading day after completion of the merger, and September 22, 2022, WBD's stock price fell by 52.4%, from $24.78 to $11.79 per share, as the market became aware of the foregoing misrepresented and omitted facts.

Next Steps: If you acquired shares of Warner Bros. Discovery, Inc. pursuant to the merger between Discovery and the WarnerMedia division of AT&T, you have until November 22, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Warner Bros. Discovery, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:WBD

Release Summary
Defendants Made False and Misleading Statements in Connection with the Merger Between Discovery, Inc. and the WarnerMedia division of AT&T, Inc.
Release Versions

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom